Last reviewed · How we verify
SV2A PET
At a glance
| Generic name | SV2A PET |
|---|---|
| Also known as | [11C]UCB-J, [11C]APP311 |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Hypertension
- Paresthesia
- Dysgeusia
- Liver function test increased
- Transient Visual Disturbance
- Pain in Extremity
- Brain Fog
- Urinary Urgency
- Cough
- Pain
- Back Pain
Key clinical trials
- SV2A Density Cannabis Use Disorder (EARLY_PHASE1)
- SV2A in Older Adults (PHASE1, PHASE2)
- Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment (PHASE2)
- Presynaptic Imaging in Major Depressive Episodes After COVID-19
- SV2 PET Imaging With [11C]APP311
- SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (PHASE1, PHASE2)
- Multimodal PET Imaging With 18F-FDG/SV2A/TSPO for Resection Planning in Drug-Resistant Epilepsy
- The Synapse Project (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SV2A PET CI brief — competitive landscape report
- SV2A PET updates RSS · CI watch RSS
- Yale University portfolio CI